ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 274,48
-0,27%
Dow Jones
42 840,26
1,18%
DAX
19 884,75
-0,57%
Brent Oil
72,72
0,00%
Bitcoin
96 700,32
-1,08%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Quince Therapeutics Inc (QNCX) Cours

Quince Therapeutics Inc

Quince Therapeutics Inc (QNCX)

NASDAQ
1,78
0,02
(1,14%)
Fermé 21 Décembre 10:00PM
Retardé de 15 minutes
1,85
0,07
(3,93%)
Après les heures de négociation: 12:42AM
Retardé de 15 minutes

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
1,85
Prix Achat
1,32
Prix Vente
5,00
Volume échangé
106 261
1,74 Fourchette du Jour 1,847
0,5116 Plage de 52 semaines 2,45
Cap du marché
81,403M
Clôture Veille
1,76
Ouverture
1,76
Dernière Transaction
70
@
1.81
Dernière heure de transaction
Volume financier
US$ 187 790
VWAP
1,7673
Volume moyen (3 m)
599 908
Actions en circulation
44 001 643
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-2,73
Bénéfice par action (BPA)
-0,71
Chiffre d'affairess
-
Bénéfice net
-31,39M

À propos de Quince Therapeutics Inc

Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug ... Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Site Web
quincetx.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Quince Therapeutics Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker QNCX. Le dernier cours de clôture d'Quince Therapeutics était de US$1,76. Au cours de la dernière année, les actions de Quince Therapeutics ont été négociées dans une fourchette de prix de US$ 0,5116 à US$ 2,45.

Quince Therapeutics compte actuellement 44 001 643 actions en circulation. La capitalisation boursière d'Quince Therapeutics est de US$77,44 million. Quince Therapeutics a un ratio cours/bénéfice (ratio PE) de -2.73.

QNCX Dernières nouvelles

Plus de nouvelles

Form S-3 - Registration statement under Securities Act of 1933

18 Décembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

14 Novembre 2024
Edgar (US Regulatory)

Form SC 13D - General Statement of Acquisition of Beneficial Ownership

14 Novembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

13 Novembre 2024
Edgar (US Regulatory)

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Phase 3 NEAT clinical trial on track with 32 patients enrolled to date with majority of U.S. and European study sites now enrolling patients Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage...

13 Novembre 2024
Business Wire

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the...

12 Novembre 2024
Business Wire

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the...

11 Novembre 2024
Business Wire

Quince Therapeutics to Participate at Upcoming Investor Conferences

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that...

14 Octobre 2024
Business Wire

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that...

03 Septembre 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

22 Août 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.2-9.756097560982.052.061.752209071.88406444CS
4-0.36-16.28959276022.212.451.682810011.96968446CS
121.0897143.3250032880.76032.450.695999081.43183185CS
261.16168.1159420290.692.450.51163601461.24642263CS
520.7872.89719626171.072.450.51162268351.20908304CS
156-10.08-84.492875104811.9314.60.51164761542.60102509CS
260-45.76-96.114261709747.61121.980.511645995313.68154864CS

QNCX - Frequently Asked Questions (FAQ)

What is the current Quince Therapeutics share price?
The current share price of Quince Therapeutics is US$ 1,85
How many Quince Therapeutics shares are in issue?
Quince Therapeutics has 44 001 643 shares in issue
What is the market cap of Quince Therapeutics?
The market capitalisation of Quince Therapeutics is USD 77,44M
What is the 1 year trading range for Quince Therapeutics share price?
Quince Therapeutics has traded in the range of US$ 0,5116 to US$ 2,45 during the past year
What is the PE ratio of Quince Therapeutics?
The price to earnings ratio of Quince Therapeutics is -2,73
What is the reporting currency for Quince Therapeutics?
Quince Therapeutics reports financial results in USD
What is the latest annual profit for Quince Therapeutics?
The latest annual profit of Quince Therapeutics is USD -31,39M
What is the registered address of Quince Therapeutics?
The registered address for Quince Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Quince Therapeutics website address?
The website address for Quince Therapeutics is quincetx.com
Which industry sector does Quince Therapeutics operate in?
Quince Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MYSZMy Size Inc
US$ 4,2001
(211,12%)
120,01M
NVNINVNI Group Ltd
US$ 8,26
(209,36%)
76,64M
TPICTPI Composites Inc
US$ 2,45
(100,82%)
33,95M
ICGIntchains Group Ltd
US$ 8,77
(88,60%)
527,61k
HSDTHelius Medical Technologies Inc
US$ 0,884851
(84,34%)
120,4M
CYNCYNGN Inc
US$ 0,4603
(-71,41%)
27,91M
MTEMMolecular Templates Inc
US$ 0,1502
(-57,09%)
8,75M
PRFXPainReform Ltd
US$ 5,15
(-53,85%)
2,94M
GALTGalectin Therapeutics Inc
US$ 1,03
(-48,50%)
9,27M
BCABBioAtla Inc
US$ 0,6923
(-41,82%)
6,25M
EDBLEdible Garden AG Inc
US$ 0,24
(65,06%)
354,33M
NVDANVIDIA Corporation
US$ 134,70
(3,08%)
310,19M
APTOAptose Biosciences Inc
US$ 0,28
(64,51%)
306,25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,606999
(6,49%)
293,22M
PLTRPalantir Technologies Inc
US$ 80,55
(8,54%)
281,23M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
QNCX
Quince Therapeutics
LSE
ZL56
Atlas 2021-1 58
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés